Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF) has thanked Tony Di Pietro for his “significant contribution” to the company after he provided notice of his resignation as chief financial officer (CFO) and company secretary.
The leader in genomics-based tests in health, wellness and serious disease has now started a search for a new CFO and company secretary with requisite dual ASX and Nasdaq-listed company expertise.
Di Pietro will remain in the dual roles until a replacement commences with GTG or at the end of March 2024, whichever date is the earliest.
“An exciting time”
On behalf of the GTG team, CEO Simon Morriss said, “Tony has made a significant contribution to the organisation since joining us in 2022 and we wish him the very best in his next endeavours.
"2024 is shaping up to be an exciting time for GTG as we focus on driving sales growth with the recent release of our comprehensive breast and ovarian cancer test in the United States and our planned Pharmacy launch in the UK.
"We will aim to seek experience in investor relations and sales growth in these target markets.”